Louise Kooij - Dec 29, 2023 Form 3 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role: Chief Accounting Officer
Signature: /s/ Louise Kooij
Stock symbol: NAMS
Transactions as of: Dec 29, 2023
Transactions value $: $0
Form type: 3
Date filed: 12/29/2023, 04:30 PM
Next filing: Jan 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	NAMS	Option (right to buy)							Dec 29, 2023	Ordinary Shares	50K	$11.90	Direct	F1
holding	NAMS	Option (right to buy)							Dec 29, 2023	Ordinary Shares	223K	$10.90	Direct	F2
holding	NAMS	Option (right to buy)							Dec 29, 2023	Ordinary Shares	430K	$10.00	Direct	F3
holding	NAMS	Option (right to buy)							Dec 29, 2023	Ordinary Shares	213K		See footnote	F4, F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on May 18, 2023. 25% of the shares underlying the option will vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
F2	The option was granted on January 1, 2023. 25% of the shares underlying the option will vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
F3	The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.
F4	The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
F5	The exercise price of the option is Euro 1.16392.
F6	The option was granted to and is held by LouFre Management B.V. ("LouFre") through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investement control over the securities held by LouFre through PoolCo. PoolCo has no voting or investement control or pecuniary interest in the securities held on behalf of LouFre.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney